RT Journal Article
SR Electronic
T1 The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 61
OP 64
DO 10.1136/ard.2008.102533
VO 69
IS 01
A1 F A Houssiau
A1 C Vasconcelos
A1 D D’Cruz
A1 G D Sebastiani
A1 E de Ramon Garrido
A1 M G Danieli
A1 D Abramovicz
A1 D Blockmans
A1 A Cauli
A1 H Direskeneli
A1 M Galeazzi
A1 A Gül
A1 Y Levy
A1 P Petera
A1 R Popovic
A1 R Petrovic
A1 R A Sinico
A1 R Cattaneo
A1 J Font
A1 G Depresseux
A1 J-P Cosyns
A1 R Cervera
YR 2010
UL http://ard.bmj.com/content/69/01/61.abstract
AB Objective: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis.Patients and methods: Data for survival and kidney function were prospectively collected during a 10-year period for the 90 patients randomised in the ELNT, except in 6 lost to follow-up.Results: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed.Conclusion: The data confirm that a LD IVCY regimen followed by AZA—the “Euro-Lupus regimen”—achieves good clinical results in the very long term.